Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Broyhill Asset Management Christopher R. Pavese | “IQVIA Holdings ($IQV) is a global leader in clinical research outsourcing, advanced healthcare analytics, and pharmaceutical commercial intelligence. Broyhill holds a high-conviction bullish stance, arguing that the market has mistakenly penalized IQVIA over generalized fears that artificial intelligence would disintermediate contract research organizations, overlooking the indispensability of its regulated proprietary clinical data. IQVIA's economic moat stems from its immense data assets, spanning over 1.2 billion non-identified patient records covering approximately 90% of worldwide prescription activity. This proprietary data repository cannot be easily replicated by generic AI algorithms, providing the company with strong pricing power and high client retention. Financially, an upcoming $300 billion pharmaceutical patent cliff acts as a structural tailwind, forcing drugmakers to aggressively invest in R&D and clinical trials to refill drug pipelines, which fueled a book-to-bill ratio of 1.22x in the second quarter. Upcoming catalysts include sustained improvement in RFP flows, clinical award delivery, and continued clinical trial bookings expansion. Key risks include macroeconomic cutbacks in discretionary biotech R&D budgets and prolonged regulatory trial approval timelines.” | BULL | Q2 2026 Sep 1, 2026 | View Pitch |
Sycamore Mid Cap Value Equity Gary H. Miller | “The company's shares fell due to conservative guidance and investor anxiety regarding artificial intelligence's impact on clinical trial workflows. The manager believes these fears are currently unproven by data and notes stabilizing biotech funding trends.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Broyhill Asset Management Christopher R. Pavese | “IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to ease. While sentiment toward the sector remains fragile, the company's role as a mission-critical infrastr” | BULL | Q4 2025 Feb 17, 2026 | View Pitch |
Broyhill Asset Management Christopher R. Pavese | “IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to ease. While sentiment toward the sector remains fragile, the company's role as a mission-critical infrastructure to drug development remains unchallenged. The first leg of the industry's recent rally was sparked by stabilization, rewarding patience through a prolonged industry downturn. We expect the next leg to gain steam as the recovery accelerates. BSD Analysis: IQVIA remains a dominant force in the life sciences sector, uniquely combining its massive healthcare data assets with industry-leading clinical research services. The company is currently trading at a notable discount to its fair value, presenting a tactical opportunity as it benefits from a surge in high-value clinical trials within the obesity and cardiometabolic space. While debt coverage remains a metric for investors to watch, IQVIA's strategic alliance with major research institutions and its AI-driven analytics platform provide a wide competitive moat. Management's focus on high-growth therapeutic areas and digital clinical trials is expected to drive meaningful margin expansion as the biotech funding environment continues to stabilize. With a valuation significantly below its historical average and peer group, the stock offers an attractive entry point for investors seeking exposure to the long-term digitization of global healthcare.” | BULL | Q4 2025 Feb 17, 2026 | View Pitch |
Harris Associates Concentrated Strategy Tony Coniaris | “IQVIA Holdings was a contributor during the quarter. The U.S.-headquartered provider of advanced analytics, solutions, and clinical research services saw its stock price appreciate after having delivered solid second-quarter results amidst a challenging pharma environment. The results reaffirmed our thesis that the technology and analytics solutions (TAS) segment is underappreciated and poised for future growth. Further the R&D solutions business showed signs of gaining share, with its win rate improving significantly. We believe forward-looking indicators are encouraging and think the company can extract further value as it leverages next-gen trends. BSD Analysis: Harris highlights IQVIA's mix of stable analytics revenue and cyclical R&D tailwinds. With EV/EBITDA ~14x and steady margin expansion, the TAS segment is driving multiple re-rating potential. Digital trials, AI-driven data use, and recurring software sales reinforce visibility.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Harris Associates Concentrated Strategy Tony Coniaris | “IQVIA was a contributor during the quarter. The U.S.-headquartered life sciences services and analytics company's stock price rose following solid first-quarter 2025 results and an improved outlook. Management emphasized continued demand for data, analytics and technology solutions from biopharma clients as well as a healthy backlog in its contract research operations. The managers believe IQVIA remains well positioned to benefit from structural growth in outsourced clinical development and real-world evidence. They continue to view the company as an attractive compounder with strong competitive advantages and high switching costs. BSD Analysis: IQVIA sits at the intersection of data, software and services for pharma and biotech customers, underpinning a durable growth profile as R&D complexity increases. Its broad data assets and integrated technology stack create a sticky ecosystem that is difficult for competitors to replicate. Despite periodic biopharma funding cycles, long-term demand for outsourced clinical and evidence-generation services remains robust. Valuation reflects its quality and growth, but continued margin expansion and disciplined capital allocation can sustain attractive returns.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
